Anti-Ny Eso-1 T Cell Receptor Cluster Of Differentiation 62L + Cells
Metastatic Cancer
National Cancer Institute (NCI)Cell therapyPhase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 73/ 100
Competitive context
276 Active assets in the Metastatic Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUOROURACILUM I-Mab Biopharma US Limited | Phase 3 | BB |
Irinotecan Incyte Corporation | Phase 3 | BB |
FILGRASTIM Mayo Clinic | Phase 3 | BB |
Pembrolizumab InSilico Medicine Hong Kong Limited | Phase 2/3 | BB |
Cyclophosphamide InSilico Medicine Hong Kong Limited | Phase 2/3 | BB |
View all 50 →
Same molecule, other indications
Anti-Ny Eso-1 T Cell Receptor Cluster Of Differentiation 62L + Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →